ICUS Weekly News Monitor 7-12-2018

1.Diagnostic Imaging, Interest in Pediatric Contrast Ultrasound Is High Among Radiologists, Jul 2, 2018

2.Clinical Radiology, The added value of contrast-enhanced ultrasound to conventional ultrasound in differentiating benign and malignant solid breast lesions: a systematic review and meta-analysis, July 2018 Authors: M. Wubulihasimu, et al

3.World Neurosurgery, Emerging Strategies and Future Perspective in Neuro-Oncology Using Transcranial Focused Ultrasonography Technology, June 8, 2018 Authors: Giada Toccaceli, et al

 

Diagnostic Imaging

Interest in Pediatric Contrast Ultrasound Is High Among Radiologists

Jul 2, 2018

Education and training are needed to support radiologists who plan to adopt contrast ultrasound for children into practice, according to the results of a survey published in the journal Pediatric Radiology.

In response to the recent approval by the United States Food and Drug Administration for an oral ultrasound contrast agent for IV and intravesical administration in children, researchers from Pennsylvania, California, Massachusetts, Tennessee, Ohio, North Carolina, Maryland, Florida, and Washington surveyed pediatric radiologists about the usage, interest in, and barriers for contrast-enhanced ultrasound in their patients.

The Contrast-Enhanced Ultrasound Task Force of the Society for Pediatric Radiology (SPR) surveyed the membership of the SPR in January 2017 regarding their current use and opinions about contrast-enhanced US in pediatrics. A total of 1,218 surveys went out and 325 responses (26.7 percent) were received.

The results showed that 166 of the 325 respondents (51.1 percent) practiced in either a university or academic affiliated group. The most widely used ultrasound contrast agent was Lumason, 52.3 percent (23/44). While lack of expertise and training were reported barriers, all respondents who were not currently using ultrasound contrast agents were considering future use.

The researchers concluded that there was high interest in using pediatric contrast in ultrasound, but education and training are needed to support members who plan to adopt contrast ultrasound into practice.

 
 
 
 
 
 

Clinical Radiology

The added value of contrast-enhanced ultrasound to conventional ultrasound in differentiating benign and malignant solid breast lesions: a systematic review and meta-analysis

July 2018

Authors: M. Wubulihasimu, M. Maimaitusun, X.-L. Xu, X.-D. Liu'Correspondence information about the author X.-D. LiuEmail the author X.-D. Liu, B.-M. Luo'Correspondence information about the author B.-M. LuoEmail the author B.-M. Luo

DOI: https://doi.org/10.1016/j.crad.2018.06.004

Abstract

Highlights

•Adding CEUS to conventional US could improve the diagnostic specificity and accuracy for breast cancers, with little reduction of the sensitivity.

•The methods of adding CEUS to the conventional US differed among studies and a uniform standard might be needed for further clinical application.

•CEUS-rerated BI-RADS might have a higher diagnostic performance in BI-RADS 3–5 lesions.

Aim

To investigate the added value of contrast-enhanced ultrasound (CEUS) to the conventional ultrasound (US) in the diagnosis of breast lesions.

Materials and methods

PubMed, EMBASE, and Web of Science were searched for relevant studies published between 24 May 2005, and 29 October 2017. Studies incorporating CEUS into the conventional US were included. The reference standard was set by means of histopathological findings. The quality assessment of diagnostic studies (QUADAS) instrument was used to assess the quality of the included studies. Meta-Disc version 1.4. was used to calculate the sensitivity, specificity, summary receiver-operating characteristic (sROC) curves, and area under the curve (AUC). Meta-regression with Stata 12.0 was used to compare the diagnostic accuracy of the two techniques.

Results

Five studies, comprising 992 patients, were eligible for this meta-analysis. For conventional US, the pooled sensitivity and specificity for were 0.87 (95% confidence interval [CI]: 0.84–0.91) and 0.80 (95% CI: 0.76–0.84), respectively, the AUC was 0.9049. For CEUS-rerated US, the pooled sensitivity and specificity were 0.93 (95% CI: 0.90–0.95) and 0.87 (95% CI: 0.84–0.90). The AUC was 0.9482. Meta-regression showed the sensitivity of CEUS-rerated US did not differ from conventional US (p=0.29), while specificity showed significant difference (p<0.01). There was evidence of between-study heterogeneity regarding sensitivity and specificity for both assessments.

Conclusions

Adding CEUS to conventional US could improve the diagnostic performance in differentiating benign from malignant solid breast lesions, whilst retaining high sensitivity, especially in Breast Imaging-Reporting and Data System (BI-RADS) 3–5 lesions. A uniform standard to distinguish benign from malignant lesions might be needed for further clinical application.

 
 
 
 
 
 

World Neurosurgery

Emerging Strategies and Future Perspective in Neuro-Oncology Using Transcranial Focused Ultrasonography Technology

Published online: June 8, 2018

World Neurosurgery, Vol. 117, p84–91

DOI: https://doi.org/10.1016/j.wneu.2018.05.239

Authors: Giada Toccaceli1,5, Roberto Delfini2, Claudio Colonnese3,4, Antonino Raco1, Simone Peschillo5

1NESMOS Departmente Division of Neurosurgery, 2 Department of Human Neurosciences, Neurosurgery, and 3 Department of Human Neurosciences, Neuroradiology, University of Rome, “Sapienza”, Rome; 4 IRCCS INMNeuromed, Pozzilli, Italy; and 5Endovascular Neurosurgery, Policlinico Umberto I, Rome, Italy

To whom correspondence should be addressed: Simone Peschillo, M.D., Ph.D.

Abstract

Highlights

•FUS conveys an ultrasound beam at target points at certain frequencies.

•The objective of the research was to apply FUS to the treatment of intracranial neoplastic diseases.

•We review the latest studies to take stock of the potential of FUS.

•New mini invasive therapies may become main players in the treatment of brain neoplasms, aided by FUS.

Background

Despite the progress achieved in recent years, the prognosis of patients with primary brain tumors remains poor. Research efforts have therefore focused on identifying more effective and minimally invasive treatment methods. Magnetic resonance–guided transcranial focused ultrasonography (MRgFUS) is a consolidated minimally invasive therapeutic technique, which has recently acquired a role also in the treatment of some nononcologic intracranial diseases.

Methods

We reviewed the latest studies to take stock of the potential of MRgFUS.

Results

The objective of the research in the last decade was to apply FUS also to the treatment of intracranial neoplastic diseases, using both the thermal effects (thermal ablation) and, above all, the ability to permeabilize the blood-brain barrier and modify the tumor microenvironment. This strategy may allow the use of drugs that are poorly active on the central nervous system or active selectively at high doses, minimize the side effects, and substantially modify the prognosis of patients affected by these diseases.

Conclusions

In the future, targeted drug delivery, immunotherapy, and gene therapy will probably become main players in the treatment of brain neoplasms, with the aid of MRgFUS. In this way, it will be possible to directly intervene on tumor cells and preserve healthy tissue.

ICUS Weekly News Monitor 6-28-2018


1.DOTmed, SonoVue approved in China for intravesical use in ultrasonography of the excretory tract to detect vesicoureteral reflux, June 21, 2018, Press release

2.Aunt Minnie, Bracco's SonoVue ultrasound contrast cleared in China, Jun 20, 2018

3.Daily American, Siemens Healthineers Launches Acuson Sequoia to Address Industry Challenges in Ultrasound Imaging, June 22, 2018

 

DOTmed

SonoVue approved in China for intravesical use in ultrasonography of the excretory tract to detect vesicoureteral reflux

June 21, 2018

Press release

Milan (Italy), June 20, 2018 - Bracco Imaging S.p.A., a global leader in diagnostic imaging, recently announced that its ultrasound contrast agent SonoVue® (sulphur hexafluoride microbubbles) has been the first approved in China for use in ultrasonography of the urinary tract (voiding ultrasonography) for the evaluation of suspected or known vesicoureteral reflux (VUR) in pediatric patients.

VUR is a urinary tract abnormality in neonates, infants and children characterized by retrograde flow of urine from the bladder into the ureter and toward the kidney and represents a common cause of recurrent urinary tract infections and chronic nephropathy in pediatric patients. Voiding cysturethrography and direct radionuclide cystography are the imaging procedures currently used to diagnose VUR, and both require exposure to ionizing radiation.

“This approval of SonoVue® for voiding ultrasonography addresses an important unmet medical need for accurate detection and follow-up of VUR, a frequent cause of urinary tract infections and renal complications in neonates, infants and young children, without exposing them to the potential harmful effects of ionizing radiation,” stated Alberto Spinazzi, MD, Head, Global Medical and Regulatory Affairs, Bracco Group.

“We are particularly proud that, after United States and Europe, now this important indication for our contrast ultrasound agent SonoVue® has been also approved in China,” said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. “This new indication for SonoVue® reflects our efforts and investments to offer significant clinical benefit by expanding the range of approved clinical indications for contrast enhanced ultrasound in China, one of the most relevant areas of development for Bracco”.

Since 2004, China has been at the forefront of research in contrast enhanced ultrasound, with the development of innovative clinical applications in various clinical scenarios and patient populations. SonoVue® is the ultrasound contrast agent most widely used in clinical studies and routine clinical practice in China, and the first and only approved for use in the pediatric population in this country.

 
 
 
 
 
 

Aunt Minnie

Bracco's SonoVue ultrasound contrast cleared in China

Jun 20, 2018

By staff writers

Contrast developer Bracco Imaging has received clearance from Chinese regulators for the use of its SonoVue (sulphur hexafluoride microbubbles) ultrasound contrast agent in ultrasonography of the urinary tract.

This clinical application of SonoVue is for evaluating suspected or known vesicoureteral reflux (VUR) in neonates, infants, and children. VUR involves the retrograde flow of urine from the bladder into the ureter and toward the kidney.

SonoVue is a second-generation ultrasound contrast agent with approved clinical indications that include cardiac, vascular, liver, and breast imaging in adults, Bracco said.

 
 
 
 
 
 

Daily American

Siemens Healthineers Launches Acuson Sequoia to Address Industry Challenges in Ultrasound Imaging

June 22,2018

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 22, 2018--Siemens Healthineers has announced the launch of its new ultrasound system, the Acuson Sequoia. The new Acuson Sequoia, a general imaging ultrasound system, was developed in response to one of the most prevalent challenges in ultrasound imaging today: the imaging of different sized patients with consistency and clarity. With its new Deep Abdominal Transducer (DAX), a new high-powered architecture, and innovative updates to elastography and contrast-enhanced ultrasound, the new Acuson Sequoia produces penetration up to 40cm. With its powerful architecture and innovative features, the new Acuson Sequoia expands precision medicine by enabling high-resolution imaging that adapts to patients’ size and personal characteristics, contributing to more confident diagnosis.

“Ultrasound imaging has been plagued by variability. Patients’ varied physical characteristics and user-dependent variabilities can impact a clinician’s ability to deliver an accurate diagnosis,” says Robert Thompson, Head of Ultrasound at Siemens Healthineers. “With the new Acuson Sequoia, Siemens Healthineers provides users with a solution that enables real-time imaging for varying patient types, including those with high BMI, without sacrificing image quality and potentially reducing the need for repeat scans and unclear diagnoses.”

Expanding the reach of ultrasound imaging

According to the World Health Organization, 1.9 billion people globally are reported as overweight with 650 million people classified as obese (with a BMI above 30). Because ultrasound imaging relies on the sending and receiving of echo signals to produce images, patients with more adipose tissue are more difficult to image. The deeper an echo signal needs to penetrate, the more attenuation occurs, resulting in image quality degradation. In attempting to overcome these challenges, clinicians have traditionally had to compromise on frame rates, resolution, or penetration of their ultrasound imaging.

In response, Siemens Healthineers built the entirely new Acuson Sequoia system to adapt to the “BioAcoustic Variations” of each patient, characteristics that include tissue density, stiffness, and absorption. The new Acuson Sequoia provides high-resolution InFocus imaging throughout the entire field of view, from the near field to the far field, in real-time. Therefore, there is no need to adjust the focal point of the scan, resulting in faster scan time without compromising frame rates and resolution. The new ultrasound system also offers high resolution color flow, up to three times the sensitivity, 1,3 and up to 20% deeper penetration.

More power for clearer images

In addition to increased rates of obesity, prevalence of liver disease is also on the rise. 1, 5 Clinicians utilize ultrasound elastography to determine shear wave speed, a parameter correlated with tissue stiffness in the liver which can correlate to chronic disease progression. Imaging in these patients can be challenging, particularly in larger patients where the signals are attenuated. The innovative power architecture of the new Acuson Sequoia provides six times the energy capacity available for shear wave elastography, enabling imaging at greater depths and a reduction in image variability.

The BioAcoustic technology of Acuson Sequoia also improves Contrast Enhanced Ultrasound (CEUS) bubble longevity. Contrast enhanced ultrasound uses microbubble-based contrast agents to improve the visualization and assessment of lesions. With the new Acuson Sequoia system, the view time of contrast agents is significantly longer, allowing clinicians more time to scan for additional incidental lesions during their examinations and with up to twice the sensitivity.

Improving workflows with user-centric technologies

As the most widely used medical imaging modality, 6 ultrasound scanning preferences vary from user to user, making it a highly-personal experience. In a collective effort to eliminate variability and long-term ergonomic injuries, Siemens Healthineers hosted 170 workshops with 365 worldwide ultrasound users to create a platform designed by the user, for the user. The new Acuson Sequoia improves workflow by introducing user-friendly features, such as gesture detecting transducers – activated by touch, automated protocols, and streamlined registration which adapts to user preferences over time. A new ergonomically designed InTune transducer family reduces operator stress while increasing comfort.

A unique new capability among diagnostic ultrasound systems, “UltraArt” provides several image choices which are automatically generated with a user’s preferred image parameter settings, right on the touch screen. The user can select the image that best matches the patient’s BioAcoustic characteristics, avoiding manual adjustment of multiple individual image parameters.

The new Acuson Sequoia offers innovative technologies, unique transducers, and user-defined features to enhance workflow and personalize medicine.

For more information on the new Acuson Sequoia ultrasound system, visitsiemens-healthineers.com/sequoia.

ICUS Weekly News Monitor 6-21-2018


1.Aging and Disease, The Value of Contrast-Enhanced Ultrasonography Combined with Real-Time Strain Elastography in the Early Diagnosis of Prostate Cancer, June 18, 2018 Authors: Ying Chang, et al

2.SciTech Europa Quarterly, The Therapeutic Ultrasound Network for Drug Delivery and Ablation Research, 13th June 2018

3.Cision, AIUM Names Richard G. Barr, MD, Next Journal Editor-in-Chief, Jun 12, 2018

 

Aging and Disease

Aging Dis. 2018 Jun 1;9(3):480-488. doi: 10.14336/AD.2017.0704.

The Value of Contrast-Enhanced Ultrasonography Combined with Real-Time Strain Elastography in the Early Diagnosis of Prostate Cancer.

June 18, 2018

Authors: Ying Chang #1, Jingchun Yang #1, Hua Hong 2, Huijuan Ma 1, Xin Cui 3, Li Chen 4.

1Departments of Ultrasonography, Xuan Wu Hospital, Capital Medical University, Beijing 100053, China; 2Departments of Ultrasonography, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, China; 3Departments of Urology, Xuan Wu Hospital, Capital Medical University, Beijing 100053, China; 4Departments of Pathology, Xuan Wu Hospital, Capital Medical University, Beijing 100053, China; #Contributed equally

Abstract

To evaluate the performance of a combination of real-time strain elastography (RTSE) and contrast-enhanced transrectal ultrasound (CETRUS) for prostate cancer detection. Patients with serum prostate-specific antigen (PSA) levels of ≥4. 0 ng/ml were prospectively enrolled between June 2014 and December 2016. 153 prostate nodules diagnosed by conventional ultrasound were prospectively enrolled and examined by CETRUS and RTSE before a biopsy. Multivariate logistic regression models were established for CETRUS, and CETRUS combined with RTSE to diagnose prostate malignancy. The diagnostic performances of CETRUS, RTSE, and their combined use were evaluated with the receiver operating characteristic (ROC) curve. The multivariate logistic regression for CETRUS combined with RTSE showed that enhanced strength, enhanced uniformity, and elasticity scores were the independent predictors of prostate malignancy. The area under the ROC curve of CETRUS combined with RTSE (0.921±0.023) was higher than that of CETRUS and RTSE (0.88±0.029 and 0.80±0.038, respectively; both p<0.05). Moreover, the sensitivity, accuracy and negative predictive value of CETRUS combined with RTSE were 92.1%, 86.2%, and 84.6%, respectively. The omission diagnostic rate of CETRUS combined with RTSE (7.9%) was reduced. And the diagnostic accuracy of CETRUS combined with RTSE was significantly higher than that of CETRUS and RTSE (p<0.05). While the diagnostic accuracy of CETRUS was close to the RTSE, the difference was not statistically significant (p>0.05). The combined RTSE with CETRUS approach significantly improved the sensitivity and overall accuracy for correctly identifying prostate cancer.

 
 
 
 
 
 

SciTech Europa Quarterly

Issue 27

The Therapeutic Ultrasound Network for Drug Delivery and Ablation Research

13th June 2018

Professor Gail ter Haar, leader of the Therapeutic Ultrasound Team at The Institute of Cancer Research, UK reflects on the impressive potential of therapeutic ultrasound and the barriers to its widespread clinical adoption.

Most people will be familiar with the ultrasound scans that often accompany the first announcement of a pregnancy to a wider family group. These are performed with the expectation that they are safe, the ultrasound exposure having no untoward consequences for the unborn baby. However, if the amount of energy used is increased, or delivered in a different fashion, biological effects can be induced, and at high enough levels, cells may be killed. These biological effects can now be harnessed for therapeutic benefit. Therapeutic ultrasound (ThUS) has enormous potential as a minimally invasive treatment modality, with current applications ranging from the treatment of cancer and stroke to fracture healing and neuromodulation. It is uniquely versatile, offering the ability to thermally ablate tissue, to mechanically fragment it or to enhance drug delivery, depending on the way in which the acoustic energy is delivered. However, despite highly promising initial trials and its considerable advantages in terms of cost and patient safety, widespread clinical adoption is slow.

The UK’s Engineering and Physical Sciences Research Council (EPSRC) has funded a network, the Therapeutic Ultrasound Network for Drug Delivery and Ablation Research (ThUNDDAR), the main focus of which is to inform the clinical community of the existence of therapy ultrasound techniques and to stimulate the translational research that will enable their potential to be fully realised.

Speaking to SciTech Europa, Professor Gail ter Haar, leader of the Therapeutic Ultrasound Team at The Institute of Cancer Research, UK, reflects on the advantages of this promising approach, the hurdles left to be overcome, and the role of ThUNDDAR moving forwards.

What therapeutic areas stand to benefit most from advanced therapeutic ultrasound?

The two broad main areas currently under most active investigation by those interested in exploiting therapeutic ultrasound’s potential are in brain (both malignant and benign conditions) and for cancer in general (both for palliation and ‘cure’), although a number of other applications are also under investigation, such as, for example, in foetal medicine and in relief of pain.

There is overlap in many of the desired effects being sought from therapeutic ultrasound in these applications. At sufficiently high acoustic powers, a highly focused beam can be used to thermally ablate tissue volumes by inducing temperatures in the region of 55°C held for times of ~1 second. This results in instantaneous cell death. These tissue regions lie solely in the focal volume, with overlying and surrounding tissues being spared. This is a truly non-invasive technique as the focus can lie deep in the body, while the ultrasound source is outside it. Commonly referred to as HIFU (high intensity focused ultrasound) or FUS (focused ultrasound surgery), this thermal ablation can be used to destroy accessible tumours with the aim of producing a cure, or of debulking large tumours in order to allow other therapies to become more effective. It has been explored in treatment of cancers in the liver, kidneys, pancreas, prostate, and brain. It has also been used for treating movement disorders (for example, essential tremor) where highly specific brain regions must be destroyed. The remaining challenges lie in finding inexpensive rapid methods for monitoring the treatment in real time, and in refining the ultrasound energy sources (transducers) for specific applications. While HIFU in the brain, and in some other cancers, is carried out clinically using magnetic resonance imaging (MRI), the refinement of simpler monitoring techniques, such as those based on ultrasound, which can be used away from major imaging centres, continues.

Ultrasound is a pressure wave, and where pressure amplitudes are sufficiently high, tissue fractionation (histotripsy) occurs. This can emulsify the cells in the focal region, again producing instantaneous cell death. This has been found to be useful, for example for destroying regions in kidneys, liver and prostate, and in cardiac applications where a discrete septal opening is required. Recently, it has also been shown that short histotripsy-type pulses can stimulate an immune response, most probably by releasing factors into the blood stream as tumour cells are disrupted.

An ultrasound pressure wave leads to oscillations of microbubbles lying in its path. This bubble activity is known to as acoustic cavitation, with gentle repetitive oscillations being referred to as stable cavitation and the more violent growth and collapse being known as inertial cavitation. The bubbles may be drawn out of the tissue or may be deliberately introduced, usually in the form of ultrasound contrast agents. Inertial cavitation is responsible for the tissue fractionation seen in histotripsy, but the stable oscillations of bubbles play an important role in enhancing drug uptake. While the mechanism for this is not fully understood, it is presumed that these bubbles change the permeability of the blood vessels in which they sit. This can lead to transient opening of the blood brain barrier (BBB) or to an increase in the amount of cytotoxic drug seen in a tumour. There is considerable interest in this as, for the first time, it allows, for example, drugs designed to treat Alzheimer’s disease to cross the BBB, or it can allow a reduction in dose of a chemotherapeutic agent for cancer treatment, thus potentially reducing side effects.

At low acoustic outputs, therapeutic ultrasound is being explored for neuromodulation and also for the selective heating of drug-filled vesicles that are designed to release their payload only in regions that are held at a required temperature, such as, for example, at the focus of an ultrasound beam whose source is outside the body.

What do you feel are the biggest barriers to a more widespread clinical adoption, and how can they be overcome?

Despite highly promising initial clinical trials and ThUS’s considerable advantages in terms of cost and patient safety, widespread clinical adoption has been hindered by a combination of factors. These include:

• Poor understanding of the mechanisms of action;

• Lack of effective treatment monitoring;

• Absence of standardised treatment protocols;

• Poor communication between basic scientists, engineers and clinicians.

However, perhaps the greatest barrier at present is the lack of weight of clinical evidence for therapeutic ultrasound’s efficacy. This is required not only to sway clinical opinion but also to allow regulatory approval. This is a ‘chicken and egg’ situation.

Considerable investment in time and money is needed to set up the required multicentric clinical trials. Without the necessary evidence this investment is hard to attract, and it is difficult to recruit sufficient centres, especially as therapy ultrasound applications are often in competition with other new techniques, such as molecular imaging and therapy. Regulatory authorities are uncertain as to the correct approval route for these devices, especially when the combination of new ultrasound techniques with new drug approaches is proposed.

The activities of ThUNDDAR have been designed to stimulate and promote collaborations which will address these issues and to draw together relevant interested parties.

How important is an interdisciplinary approach? How difficult is this to achieve and maintain?

An interdisciplinary approach is essential: this field cannot progress without close collaboration between specialists in the physical and biological sciences. Preclinically, novel approaches come from, for example, physicists, engineers, biologists, chemists, immunologists, and pharmacologists working together. It is necessary to understand the physics of the interaction of ultrasonic waves with tissue structures, and with bubbles, to be able to construct devices that can deliver specific ultrasound exposures and to develop vehicles that can promote the locally enhanced deposition of, for example, cytotoxic drugs. Current clinical treatments require the involvement of the referring clinician (usually a neurosurgeon or oncologist), a radiologist, and a radiographer to define the treatment position and deliver the treatment, a physicist or engineer to advise on the exposure conditions, and an anaesthetic team. In busy hospitals, it can require considerable forward planning to assemble such a team. Each specialist plays an essential role in the successful delivery of the treatment.

What have been ThUNDDAR’s biggest achievements so far?

ThUNDDAR has provided seed funding for a number of pilot projects. This has allowed groups that have not previously worked together to develop innovative ideas and to obtain pilot results that will allow them to apply for larger grants from more conventional funding bodies.

We have also held events that have drawn together industry, clinicians, and academics with the aim of introducing these groups to the potential of therapy ultrasound. These have been well attended, and although they have been effective at introducing and informing people, keeping up the momentum from such initiatives is very time-consuming and difficult. At a time when all practitioners in the NHS are being pushed more and more to deliver more and more work in all aspects without any change in funding, this type of initiative becomes more challenging to bring to a successful conclusion.

Where will your future priorities lie?

We will continue to fund pilot projects as the field will not progress without drawing new blood into it. We also have plans to hold joint meetings with other disciplines and networks. An example of this is our planned meeting which will be co-hosted with the EPSRC Image-Guided Therapies UK Network+.

We are present at relevant clinical conferences, offering to run sessions and to provide expert lecturers as, and when, appropriate. It is key that the wider community understands the considerable promise that therapy ultrasound can offer in its many guises.

Professor Gail Ter Haar, Therapeutic Ultrasound Team, The Institute of Cancer Research

+44 (0)20 8661 3703;  This email address is being protected from spambots. You need JavaScript enabled to view it.

 
 
 
 
 
 

Cision

AIUM Names Richard G. Barr, MD, Next Journal Editor-in-Chief

Jun 12, 2018

NEWS PROVIDED BY AIUM

LAUREL, M.D., June 12, 2018 /PRNewswire/ -- The American Institute of Ultrasound in Medicine (AIUM) is proud to announce that Richard G. Barr, MD, PhD, FAIUM, FSRU, FACR, will be the next editor-in-chief of the Journal of Ultrasound in Medicine (JUM).

"We are excited to have someone with Dr Barr's knowledge and expertise as the next editor of the JUM," said AIUM President Brian Coley, MD, FAIUM. "We know that Dr Barr will build on JUM's success and continue to represent all areas of medical ultrasound."

A regular contributor to, and reviewer for, the JUM, Dr Barr has a diverse background that is well suited for its continued growth. Dr Barr is a board certified Radiologist and PhD Chemist who currently serves as Assistant Chairman of the Department of Radiology at Northside Medical Center, and as President of Radiology Consultants Inc., both in Ohio. In addition, Dr Barr is a Professor of Radiology at Northeastern Ohio Medical University.

Dr Barr received his PhD from Michigan State University, his MD from Case Western Reserve University, did his residency at the Cleveland Clinic foundation in Diagnostic Radiology where he served as the chief resident, and completed a fellowship at University of San Francisco in cross sectional imaging.

Dr Barr is a fellow of the AIUM, SRU, and ACR whose interests include breast imaging, contrast-enhanced ultrasound, and elastography. He has published more than 100 scientific articles and has given more than 300 talks around the world. He received a 2017 RSNA Honored Educator award and Aunt Minnie named him a semifinalist for the most influential Radiology Researcher in 2017.

"I look forward to serving as editor-in-chief for the JUM," said Barr. "My predecessors have done an excellent job creating an international journal for all ultrasound subspecialties. I hope to continue this great work while increasing the readership and quality of the content."

Dr Barr has selected Michael Blaivas, MD, FAIUM; Flemming Forsberg, PhD, FAIUM; Wesley Lee, MD, FAIUM; Mark Lockhart, MD, FAIUM; and Andrej Lyshchik, MD, PhD as his deputy editors.

Dr Barr's tenure as editor-in-chief will officially begin January 1, 2019.

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

samsung-logo

siemens-new-original

philips-icus-logo

Contact ICUS

  • Address:  International Contrast Ultrasound Society
    c/o Dentons
    233 S. Wacker Drive, Suite 5900 Chicago, IL 60606-6361
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS Weekly News